Cadmium and aflatoxin B (AFB) are both common and widespread pollutants in food and feed. There are several reports on toxicity induced by Cadmium or AFB alone, but few address the toxicity caused by co-exposure to the two substances. In this study, 42 female and 42 male Kunming (KM) mice were divided into seven groups to test the acute oral toxicity of CdCl and AFB, using Karber's method. The combined toxicity was assessed using the Keplinger evaluation system. Acute toxicity symptoms, deaths, and body and organ weights were evaluated, and hematological, blood biochemical, and histopathological analyses were conducted. The results revealed the following median lethal doses (LD): LD = 62.56 mg/kg; LD = 48.79 mg/kg; LD=55.27 mg/kg. The combined toxicity of AFB and CdCl showed an additive effect in mice, and an increase in the mixed dose of AFB and CdCl resulted in greater toxicity. These results demonstrated that the combined toxicity of AFB and CdCl was greater than the toxicities of the individual components in mice; thus, this may cause particular challenges when addressing these hazards in food and feed and the associated risk to human and animal health.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fct.2019.110577 | DOI Listing |
Curr Microbiol
January 2025
Molecular Biology Laboratory, Department of Microbiology, Science Campus, Alagappa University, Karaikudi, Tamil Nadu, 630003, India.
Antimicrobial resistance (AMR) is an escalating global health concern that results in approximately 700,000 deaths annually owing to drug-resistant infections. It compromises the effectiveness of conventional antibiotics, as well as fundamental medical procedures, such as surgery and cancer treatment. Phytochemicals, natural plant constituents, and biogenic nanoparticles synthesized through biological processes are pharmacological alternatives for supplementing or replacing traditional antibiotics.
View Article and Find Full Text PDFVenetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.
View Article and Find Full Text PDFMol Ther
January 2025
College of Veterinary Medicine, Jeonbuk National University, 79 Gobong-ro, Iksan City, Jeollabuk-do, 54596, Republic of Korea. Electronic address:
Cancer immunotherapy has revolutionized cancer treatment due to its precise, target-specific approach compared to conventional therapies. However, treating solid tumors remains challenging as these tumors are inherently immunosuppressive, and their tumor microenvironment (TME) often limits therapeutic efficacy. Interestingly, certain bacterial species offer a promising alternative by exhibiting an innate ability to target and proliferate within tumor environments.
View Article and Find Full Text PDFSci Rep
January 2025
School of Public Health, Chongqing Medical University, Chongqing, China.
Cumulative risk assessment is significant for evaluating the combined exposure to multiple substances, but its widespread acceptance and application have been limited due to the complexity of clarifying and assessing actual exposure. In this study, we conducted a cumulative risk assessment based on hazard-driven criteria to evaluate the co-exposure to elemental contaminants in the diet of the population in Chongqing Municipality. The cumulative risk was calculated and evaluated using Monte Carlo modeling and the modified Reference Point Index (mRPI) method.
View Article and Find Full Text PDFClin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!